LOX Systemic Inhibitor

LOX Systemic Inhibitor - myelofibrosis and pancreatic cancer

Pharmaxis has developed an oral drug inhibiting all lysyl oxidase family members. The compound has shown significant reductions in fibrosis in in-vivo models of kidney fibrosis, lung fibrosis, myelofibrosis and pancreatic cancer. Whereas the Pharmaxis selective LOXL2 inhibitors are suited to chronic fibrotic conditions such as IPF and NASH, this all-encompassing LOX inhibitor is well positioned for the treatment of severe fibrosis as well as cancer with prominent stroma (connective tissue) or fibrotic metastatic niches. Pharmaxis plans to initially develop the compound for pancreatic cancer.

Pharmaxis is collaborating with Garvan Institute of Medical Research to investigate the therapeutic potential of LOX inhibition in pancreatic cancer.

The preclinical package on the compound has been completed and an ethics submission to enable progress into a Phase 1 clinical trial in healthy volunteers has been filed. The trial is planned to commence in the first quarter of 2019.

Watch a presentation on Fibrosis, LOX and Cancer by Dr Thomas R. Cox, Leader of the Matrix and Metastasis Team, Garvan Institute of Medical Research.

Watch a presentation on the Pharmaxis LOX program by Pharmaxis Head of Drug Discovery - Dr Wolfgang Jarolimek.

Access Pharmaxis Publications and Posters on LOX inhibitors

Skip to

Fibrosis

Phase I
Description Phase 1 Trial
Sites to be determined
Subjects to be determined
Status In progress
More Information

Planned to commence in the first quarter of 2019

Media Releases